Brief: Ascletis Pharma Updates On Study For Oral 3CLPRO Inhibitor ASC11 For COVID-19
16/01/2023 01:03
Jan 16 (Reuters) - Ascletis Pharma Inc 1672.HK :
* UPDATES ON STUDY FOR ORAL 3CLPRO INHIBITOR ASC11 FOR
COVID-19
* DOSING OF 4 HEALTHY SUBJECTS OF FIRST COHORT IN
MULTIPLE-DOSE
ESCALATION PHASE I CLINICAL TRIAL
Source text for Eikon: ID:nHKS1nCYJD
Further company coverage: 1672.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ascletis Pharma
See all newsFactbox: Race to launch weight-loss pill heats up as Novo wins UK approval
Brief: Ascletis Announces Fixed-Dose Combination of ASC30, Once-Daily Oral Small Molecule GLP-1R Agonist, and ASC39, Once-Daily Oral Small Molecule Amylin-Selective Amylin Receptor Agonist, for Clinical Development
Factbox: Race to launch weight-loss pill heats up as Lilly wins US approval
Brief: Ascletis Pharma FY Loss Attributable Rmb359.9 Million
Brief: Ascletis Pharma Expects To Submit IND Application To U.S. FDA For ASC39 In Q3 2026